Health Care • Biotechnology: Pharmaceutical Preparations
$174.40 ▲ +4.89
(+2.89%)
MKT CAP: $270.45B • VOL: 3.72M
52W L $153 52W H $213
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$147
MEDIAN
$195
MEAN
$199
HIGH
$237
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE AZN TAPE
AZN // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $211.02 | $200.56 | 2025-02-14 | $158.70 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $219.74 | $205.79 | 2025-02-06 | $163.94 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $198.82 | $191.84 | 2025-01-29 | $167.42 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $177.89 | — | 2025-01-17 | $170.91 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $153.47 | $165.68 | 2025-01-09 | $155.22 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $207.54 | $181.38 | 2024-12-18 | $151.73 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $169.17 | $176.14 | 2024-12-04 | $162.19 | -4.3% | 48% | C |